Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine September 2014, 55 (9) 8A;
  • Article
  • Info & Metrics
  • PDF
Loading

Stuck in a V/Q rut? Graham offers a wake-up call and rationale for consideration of changing from conventional planar imaging to SPECT for ventilation–perfusion lung studies.

Page 1395

α-synuclein radiotracers: Shah and colleagues provide an overview of current developments in and future potential for brain imaging targeting the α-synuclein protein in a range of neurodegenerative diseases.

Page 1397

Choline imaging in prostate cancer: Mansi and colleagues contribute perspectives on the current clinical utility of choline-based PET imaging in diagnosis, staging, and prognosis in prostate cancer and assess the potential of hybrid modalities and alternative radiotracers.

Page 1401

90Y-resin radioembolization: Devcic and colleagues report on the results of a meta-analysis of published literature on the efficacy of 90Y-resin radioembolization in patients with liver-dominant metastatic neuroendocrine tumors.

Page 1404

Head and neck PET/CT interpretation: Marcus and colleagues provide data validating the Hopkins interpretation criteria for PET/CT assessment of therapy response and survival outcomes in patients with head and neck squamous cell cancer.

Page 1411

18F-FLT PET/CT in NSCLC: Frings and colleagues detail simplified quantitative parameters of 18F-FLT uptake in patients with non–small cell lung cancer before and after initiation of treatment with a tyrosine kinase inhibitor.

Page 1417

11C-choline PET/CT and salvage RT: Castellucci and colleagues identify factors that influence the rate of 11C-choline PET/CT detection of recurrent prostate cancer in patients in early-phase biochemical relapse under consideration for salvage radiation therapy.

Page 1424

MILLISIEVERT Study: Einstein and colleagues provide results from this multi-institutional study comparing image quality, interpretation, total perfusion deficit, and ejection fraction in patients receiving both ultra-low-dose imaging on a high-efficiency SPECT camera and standard low-dose Anger SPECT imaging.

Page 1430

18F-flurpiridaz absolute MBF in humans: Packard and colleagues detail a new approach to quantitation of myocardial blood flow with PET, taking advantage of the early kinetics and high first-pass extraction of this radiotracer by the myocardium.

Page 1438

First-in-human LMI1195 PET data: Sinusas and colleagues report on human safety, whole-organ biodistribution, and radiation dosimetry for this novel 18F-labeled norepinephrine transporter ligand intended for use in mapping cardiac nerve terminals

Page 1445

90Y PET/CT reconstruction bias: Tapp and colleagues examine current quantitative limitations in PET/CT evaluation of postradioembolization 90Y distribution in the liver and describe the feasibility of an alternative approach.

Page 1452

Fetal and maternal PET dosimetry: Xie and Zaidi use new-generation pregnant phantoms as input to calculate organ and tissue S values for 9 PET radionuclides as well as fetal/maternal absorbed and effective doses from 21 radiotracers at different gestation periods.

Page 1459

Angiogenesis imaging in moyamoya: Kim and colleagues perform angiogenesis imaging in indirect revascularization surgery for pediatric moyamoya disease to evaluate angiogenic activity and its correlation with treatment efficacy.

Page 1467

18F-FDG and MR pediatric tumor imaging: Zukotynski and colleagues document 18F-FDG uptake across a spectrum of pediatric brain tumors and correlate 18F-FDG PET with MR imaging variables, progression-free survival, and overall survival.

Page 1473

Optimum LBM correction for SUV: Tahari and colleagues provide data favoring a specific optimal lean body mass formulation for normalizing standardized uptake values in clinical PET, with special relevance to increasing rates of obesity.

Page 1481

Radioiodine and alternate thyroid therapy: Pryma and Mandel offer an educational overview of the current role of radioactive iodine therapy, including patient selection and preparation, assessment of outcomes, and status of alternate or adjunctive therapeutics.

Page 1485

One-step 225Ac mAb labeling: Maguire and colleagues detail an efficient, single-step radiolabeling method for production of therapeutically active conjugates of antibodies with 225Ac at high specific activity, with promise for targeted therapy in a range of cancers.

Page 1492

18F-labeled octreotate: Liu and colleagues report on an alkyltrifluoroborate–octreotate conjugate that is radiolabeled in a 1-step 18F exchange reaction in high yield and with high specific activity, with potential for clinical PET imaging in neuroendocrine tumors.

Page 1499

18F-FPIA tumor detection: Witney and colleagues detail the design of and initial animal studies with a new probe for cancer detection and imaging of aberrant lipid metabolism.

Page 1506

Development of 11C-Lu AE92686: Kehler and colleagues report on discovery and initial validation of this novel phosphodiesterase 10A ligand and its tritiated analog, with implications for PET imaging of brain function.

Page 1513

Dual-labeled MN-14 image-guided surgery: Rijpkema and colleagues demonstrate the preclinical feasibility of image-guided resection of carcinoembryonic antigen–expressing tumors using this 111In- and fluorescence-labeled agent.

Page 1519

PET and VEGFR: Li and colleagues describe the synthesis and initial preclinical performance of 64Cu-labeled probes based on a kinase inhibitor already in clinical use, for development of a vascular endothelial growth factor receptor–selective theranostic radiopharmaceutical.

Page 1525

11C-PBB3 radiosynthesis: Hashimoto and colleagues establish protocols for radiosynthesis and quality control of this agent for in vivo imaging of tau pathology in the human brain and characterize its photoisomerization, biodistribution, and metabolism.

Page 1532

Imaging slowly diffusing radiotracers: Wilks and colleagues investigate the effects of subvoxel spatial heterogeneity on measured time–activity curves in PET imaging and the effects of ignoring diffusion limitation on parameter estimates from kinetic modeling.

Page 1539

Multimodality imaging and metastatic rhabdomyosarcoma: Armeanu-Ebinger and colleagues validate PET/MR imaging using optical imaging in a disseminated rhabdomyosarcoma mouse model.

Page 1545

Robotic-assisted SLN fluorescence imaging: Liss and colleagues determine the ability of the FireFly camera system to detect fluorescent sentinel lymph nodes after administration of a dual-labeled molecular imaging agent in an animal model.

Page 1552

MIRDcell V2.0: Vaziri and colleagues describe a software application that models the distribution of radiopharmaceuticals in tissues, calculates distribution of radiation dose, models responses on a cell-by-cell basis, and predicts the surviving fraction of labeled and unlabeled cell populations.

Page 1557

  • © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 55 (9)
Journal of Nuclear Medicine
Vol. 55, Issue 9
September 1, 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Sep 2014, 55 (9) 8A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Sep 2014, 55 (9) 8A;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • Preclinical Evaluation of Robotic-Assisted Sentinel Lymph Node Fluorescence Imaging
  • Fetal and Maternal Absorbed Dose Estimates for Positron-Emitting Molecular Imaging Probes
  • Discovery and Development of 11C-Lu AE92686 as a Radioligand for PET Imaging of Phosphodiesterase10A in the Brain
  • Is Radiocholine PET/CT Already Clinically Useful in Patients with Prostate Cancer?
  • Efficient 1-Step Radiolabeling of Monoclonal Antibodies to High Specific Activity with 225Ac for α-Particle Radioimmunotherapy of Cancer
  • SPECT- and Fluorescence Image–Guided Surgery Using a Dual-Labeled Carcinoembryonic Antigen–Targeting Antibody
  • Improved Modeling of In Vivo Kinetics of Slowly Diffusing Radiotracers for Tumor Imaging
  • Preclinical Evaluation of a High-Affinity 18F-Trifluoroborate Octreotate Derivative for Somatostatin Receptor Imaging
  • The Impact of Image Reconstruction Bias on PET/CT 90Y Dosimetry After Radioembolization
  • Radioiodine Therapy for Thyroid Cancer in the Era of Risk Stratification and Alternative Targeted Therapies
  • 18F-FDG PET and MR Imaging Associations Across a Spectrum of Pediatric Brain Tumors: A Report from the Pediatric Brain Tumor Consortium
  • In Vivo Evaluation of Angiogenic Activity and Its Correlation with Efficacy of Indirect Revascularization Surgery in Pediatric Moyamoya Disease
  • Ventilation–Perfusion Lung Scanning: Stuck in a Rut?
  • Biodistribution and Radiation Dosimetry of LMI1195: First-in-Human Study of a Novel 18F-Labeled Tracer for Imaging Myocardial Innervation
  • A Tyrosine Kinase Inhibitor–Based High-Affinity PET Radiopharmaceutical Targets Vascular Endothelial Growth Factor Receptor
  • MIRD Pamphlet No. 25: MIRDcell V2.0 Software Tool for Dosimetric Analysis of Biologic Response of Multicellular Populations
  • Head and Neck PET/CT: Therapy Response Interpretation Criteria (Hopkins Criteria)—Interreader Reliability, Accuracy, and Survival Outcomes
  • Optimum Lean Body Formulation for Correction of Standardized Uptake Value in PET Imaging
  • The Efficacy of Hepatic 90Y Resin Radioembolization for Metastatic Neuroendocrine Tumors: A Meta-Analysis
  • Early Biochemical Relapse After Radical Prostatectomy: Which Prostate Cancer Patients May Benefit from a Restaging 11C-Choline PET/CT Scan Before Salvage Radiation Therapy?
  • Molecular Imaging Insights into Neurodegeneration: Focus on α-Synuclein Radiotracers
  • Comparison of Image Quality, Myocardial Perfusion, and Left Ventricular Function Between Standard Imaging and Single-Injection Ultra-Low-Dose Imaging Using a High-Efficiency SPECT Camera: The MILLISIEVERT Study
  • Assessment of Simplified Methods to Measure 18F-FLT Uptake Changes in EGFR-Mutated Non–Small Cell Lung Cancer Patients Undergoing EGFR Tyrosine Kinase Inhibitor Treatment
  • Absolute Quantitation of Myocardial Blood Flow in Human Subjects With or Without Myocardial Ischemia Using Dynamic Flurpiridaz F 18 PET
  • Radiosynthesis, Photoisomerization, Biodistribution, and Metabolite Analysis of 11C-PBB3 as a Clinically Useful PET Probe for Imaging of Tau Pathology
  • Preclinical Evaluation of 3-18F-Fluoro-2,2-Dimethylpropionic Acid as an Imaging Agent for Tumor Detection
  • PET/MR Imaging and Optical Imaging of Metastatic Rhabdomyosarcoma in Mice
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire